Nuvalent submits two NDAs, extends cash runway to 2029 as losses rise 29% on commercialization build

Filed May 7, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 8, 2025 · ~2 min read

Key Changes

• high

  FDA accepted zidesamtinib NDA in November 2025 with PDUFA target action date of September 18, 2026; neladalkib NDA submitted April 2026. Both filings mark transition from clinical development to potential commercial approval.

  Risk Factors: NDA submissions verify on EDGAR →
• high

  Cash runway extended from 2028 to 2029 despite Q1 net loss rising 29% to $109.3M (from $84.6M prior year) on higher R&D and commercialization expenses. Annual loss jumped 63% to $425.4M.

  MD&A: Cash runway & operating expenses verify on EDGAR →
• high

  Initiated ALKAZAR Phase 3 trial in July 2025, a 450-patient head-to-head study of neladalkib versus alectinib in first-line ALK-positive NSCLC, expanding commercial opportunity beyond TKI pre-treated population.

  MD&A: ALKAZAR trial verify on EDGAR →